Travere reports Q4 net income of $2.7M; FILSPARI sales up 108% YoY to $103.3M

Travere Therapeutics, Inc.

2025-FY EPS reported -$0.29 vs consensus -$0.12 ▼ miss (-140.9%)

FILSPARI U.S. net product sales $103.3M in Q4 2025 (+108% YoY); full year $322M (+144%).
Q4 GAAP net income $2.7M ($0.03/share) vs net loss $60.3M in Q4 2024; non-GAAP net income $33.3M.
PDUFA target for FILSPARI in FSGS is April 13, 2026; commercial launch preparations ongoing.
Cash & securities $322.8M at Dec 31, 2025; expects $25M milestone from Mirum in H1 2026.
Phase 3 HARMONY study of pegtibatinase in HCU resumed enrollment; primary endpoint tHcy change.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.